April 23rd 2024
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
February 12th 2024
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
B-ALL Hispanic Population Underrepresented in Hospital CAR T Referrals
April 13th 2023Investigators highlight the importance of building partnerships between CAR T-cell centers and external hospitals to increase treatment referrals and access to clinical trials for patients with B-cell acute lymphoblastic leukemia.
FDA Accepts Remestemcel-L BLA Resubmission for Pediatric Acute GVHD
March 8th 2023The FDA initially issued a complete response letter for remestemcel-L in pediatric steroid-refractory acute graft-versus-host disease in October 2020, citing a need for an additional randomized, controlled trial to confirm the agent’s efficacy.
NCCN Guidelines Update Includes Injection for Cisplatin Ototoxicity in AYAs
February 14th 2023A medical oncologist and research audiologist from St. Jude Children’s Research Hospital discuss how sodium thiosulfate injection may improve quality of life by preventing cisplatin-associated ototoxicities in pediatric patients with localized non-metastatic tumors, although more research is needed.
FDA Grants Orphan Drug Exclusivity to Sodium Thiosulfate Injection for Pediatric Cancer
February 1st 2023The FDA gives orphan drug exclusivity to sodium phosphate injection for the prevention of cisplatin-related hearing loss in pediatric patients 1 month and older with localized, non-metastatic solid tumors.